HISERPIA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for HISERPIA (HISERPIA).
HISERPIA (risperidone) is an atypical antipsychotic that acts as a serotonin 5-HT2A and dopamine D2 receptor antagonist. It also binds to alpha1-adrenergic and histamine H1 receptors with high affinity, contributing to its therapeutic and side effect profile.
| Metabolism | Primarily metabolized by CYP2D6 and CYP3A4 to its major active metabolite, 9-hydroxyrisperidone (paliperidone). CYP2D6 poor metabolizers have higher risperidone levels. Minor pathways include N-dealkylation. |
| Excretion | Primarily renal (60-70% as unchanged drug) and biliary/fecal (20-30% as metabolites). |
| Half-life | Terminal elimination half-life is 12-15 hours; clinically, steady-state is reached after 2-3 days of regular dosing. |
| Protein binding | Approximately 90% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 1.5-2.5 L/kg; indicates extensive tissue distribution. |
| Bioavailability | Oral: 80-95% due to extensive absorption with limited first-pass metabolism. |
| Onset of Action | Oral: 30-60 minutes; intravenous: 5-15 minutes. |
| Duration of Action | Oral: 6-12 hours; intravenous: 4-6 hours; duration may be prolonged in hepatic impairment. |
Initial: 0.25 mg orally twice daily; increase gradually to usual maintenance dose of 0.5–2 mg/day in divided doses. Maximum: 3 mg/day.
| Dosage form | TABLET |
| Renal impairment | No specific guidelines; use with caution in severe renal impairment (CrCl <30 mL/min) due to potential for accumulation. |
| Liver impairment | Child-Pugh Class A: no adjustment; Class B: reduce dose by 50%; Class C: avoid use. |
| Pediatric use | Not recommended for children under 12 years; limited data available. |
| Geriatric use | Start at 0.125 mg orally twice daily; increase slowly due to increased sensitivity and risk of hypotension. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for HISERPIA (HISERPIA).
| Breastfeeding | Contraindicated in breastfeeding; excreted in human milk with M/P ratio >1 (2.5 based on limited data). Potential for severe adverse effects in the nursing infant, including kernicterus. |
| Teratogenic Risk | First trimester: Case reports of major congenital malformations including neural tube defects and cardiovascular anomalies, likely due to inhibition of folate metabolism. Second and third trimesters: Associated with oligohydramnios, fetal renal dysfunction, and skull ossification defects. Risk category X. |
■ FDA Black Box Warning
Increased risk of death in elderly patients with dementia-related psychosis. HISERPIA is not approved for this population.
| Serious Effects |
["Hypersensitivity to risperidone or any component of the formulation","Use in elderly patients with dementia-related psychosis (due to black box warning)"]
| Precautions | ["Cerebrovascular adverse events (including stroke) in elderly dementia patients","Neuroleptic Malignant Syndrome (NMS)","Tardive dyskinesia","Hyperglycemia and diabetes mellitus","Hyperprolactinemia","Orthostatic hypotension","Seizures","Leukopenia/neutropenia/agranulocytosis","Body temperature dysregulation","Dysphagia","Priapism"] |
Loading safety data…
| Fetal Monitoring |
| Maternal: CBC, LFTs, renal function, serum drug levels (if available), fetal surveillance: serial ultrasound for growth, amniotic fluid index, and fetal echocardiography. Consider nonstress test or biophysical profile in third trimester. |
| Fertility Effects | May impair spermatogenesis and oogenesis based on animal studies; human data limited. Reversible upon discontinuation. May disrupt menstrual cycle. |